

The listing of claims will replace all prior versions, and listings, of claims in the application:

Listing of Claims:

Claim 1 (Currently Amended): A method of compensating for an absolute or relative testosterone deficiency in a patient who has said testosterone deficiency with simultaneous prophylaxis in said patient for the development of a benign prostatic hyperplasia or a prostate cancer comprising administering to said patient a combination of an androgenically effective amount of a natural or synthetic androgen, and a gestagenically effective amount of a gestagen, ~~an antigestagen, an antiestrogen, a GnRH analog, a testosterone 5 α -reductase inhibitor, an α -andreno-receptor blocker or a phosphodiesterase inhibitor.~~

Claim 2 (Previously Presented): A method according to claim 1, wherein the natural androgen component is testosterone, testosterone undecanoate, dehydroepiandrosterone, dehydroepiandrosterone sulfate, testosterone propionate, testosterone enanthate, testosterone buciclate, testosterone cypionate or androstene dione.

Claim 3 (Previously Presented): A method according to claim 1, wherein the synthetic androgen component is 17-methyltestosterone, fluoxymesterone, danazol, mesterolone, nandrolone decanoate, nandrolone phenylpropionate, oxandrolone, oxymetholone, or stanazolol.

Claim 4 (Currently Amended): A method according to claim 1, wherein the gestagen component is dienogest, levonorgestrel, gestodene, desogestrel, norgestimate, norethisterone, a norethisterone ester, ~~levonorgestrel~~, progesterone, chloromadinone acetate, cyproterone acetate, medroxy progesterone acetate, megestrol acetate, dydrogesterone, trimegestone or nomegestrol.

Claims 5-11 (Canceled)

Claim 12 (Previously Presented): A method of claim 1 wherein said combination is used in the form of a tablet, capsule, coated tablet, transdermal therapy system, ampoule, suppository, gel, ointment, nose drop, implant, pressed part or biodegradable microspheres.

Claim. 13-14 (Canceled)

Claim 15 (Previously Presented): A method of claim 4 wherein the dosage of androgen is 250-1500 mg i.m. every 4 to 14 weeks and the dosage of gestagen is 20 µg to 20 mg.

Claim 16 (Currently Amended): A method of claim 2 ~~13~~ wherein the dosage of androgen is 250-1500 mg i.m. every 4 to 14 weeks and the dosage of gestagen is 20 µg to 20 mg.

Claims 17-19 (Canceled)

Claim 20 (Currently Amended): A method of compensating for an absolute or relative testosterone deficiency in a patient who has said testosterone deficiency with simultaneous prophylaxis in said patient for the development of a benign prostatic hyperplasia or a prostate cancer comprising administering to said patient a combination of ~~a natural or synthetic androgen, testosterone~~ and dienogest, ~~an antigestagen, an antiestrogen, a GnRH analog, a testosterone 5α-reductase inhibitor, an α-andreno-receptor blocker or a phosphodiesterase inhibitor.~~

Claims 21-31 (Canceled)

Claim 32 (New): A method according to claim 1, wherein the gestagen is dienogest.

Claim 33 (New): A method according to claim 1, wherein the gestagen component is dienogest, chloromadinone acetate or cyproterone acetate and the natural androgen component is testosterone propionate.

Claim 34 (New): A method according to claim 32, wherein prophylaxis for the development of a prostate cancer is achieved.

Claim 35 (New): A method according to claim 33, wherein prophylaxis for the development of a benign prostatic hyperplasia is achieved.

Claim 36 (New): A method of claim 1 wherein the gestagen in the combination is used in the form of a tablet, capsule, coated tablet, ampoule, suppository, gel, nose drop, implant, pressed part or biodegradable microspheres.

Claim 37 (New): A method according to claim 1, wherein the androgen component is 17β -hydroxy- 17α -methyl-estra-4,9,11-trien-3-one.